| Name | Title | Contact Details |
|---|
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.
CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.
Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.